Chait Jesse, Tenorio Emanuel R, Kawajiri Hidetake, Lima Guilherme B B, Cirillo-Penn Nolan C, Bagameri Gabor, Pochettino Alberto, DeMartino Randall R, Oderich Gustavo S, Mendes Bernardo C
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN, USA.
Division of Vascular and Endovascular Surgery, Department of Cardiothoracic & Vascular Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
J Endovasc Ther. 2025 Apr;32(2):503-512. doi: 10.1177/15266028231181211. Epub 2023 Jun 14.
To describe a single-center experience of "complete aortic repair" consisting of surgical or endovascular total arch replacement/repair (TAR) followed by thoracoabdominal fenestrated-branched endovascular aortic repair (FB-EVAR).
We reviewed 480 consecutive patients who underwent FB-EVAR with physician-modified endografts (PMEGs) or manufactured stent-grafts between 2013 and 2022. From those, we selected only patients treated with open or endovascular arch repair and distal FB-EVAR for aneurysms involving the ascending, arch and thoracoabdominal aortic segments (zones 0-9). Manufactured devices were used under an investigational device exemption protocol. Endpoints included early/in-hospital mortality, mid-term survival, freedom from secondary intervention, and target artery instability.
There were 22 patients, 14 men and 8 women with a median age of 72±7 years. Thirteen postdissection and 9 degenerative aortic aneurysms were repaired with a mean maximum diameter of 67±11 mm. Time from index aortic procedure to aneurysm exclusion was 169 and 270 days in those undergoing 2- and 3-stage repair strategies, respectively. The ascending aorta and aortic arch were treated with 19 surgical and 3 endovascular TAR procedures. Three (16%) surgical arch procedures were performed elsewhere, and perioperative details were unavailable. Mean bypass, cross-clamp, and circulatory arrest times were 295±57, 216±63, and 46±11 minutes, respectively. There were 4 major adverse events (MAEs) in 2 patients: both required postoperative hemodialysis, 1 had postbypass cardiogenic shock necessitating extracorporeal membrane oxygenation, and the other required evacuation of an acute-on-chronic subdural hematoma. Thoracoabdominal aortic aneurysm repair was performed with 17 manufactured endografts and 5 PMEGs. There was no early mortality. Six (27%) patients experienced MAEs. There were 4 (18%) cases of spinal cord injury with 3 (75%) experiencing complete symptom resolution before discharge. Mean follow-up was 30±17 months in which there were 5 patient deaths-0 aortic related. Eight patients required ≥1 secondary intervention, and 6 target arteries demonstrated instability (3 IC, 1 IIIC endoleaks; 2 TA stenoses). Kaplan-Meier 3-year estimates of patient survival, freedom from secondary intervention, and target artery instability were 78±8%, 56±11%, and 68±11%, respectively.
Complete aortic repair with staged surgical or endovascular TAR and distal FB-EVAR is safe and effective with satisfactory morbidity, mid-term survival, and target artery outcomes.Clinical ImpactThe presented study demonstrates that repair of the entirety of the aorta - via total endovascular or hybrid means- is safe and effective with low rates of spinal cord ischemia. Cardiovascular specialists within comprehensive aortic teams at should feel confident that staged repair of the most complex degenerative and post-dissection thoracoabdominal aortic aneurysms can be safely performed in their patients with complication profile similar to that of less extensive repairs. Meticulous and intentional case planning is imperative for immediate and long-term success.
描述一种“全主动脉修复”的单中心经验,该修复包括外科手术或血管腔内全弓置换/修复(TAR),随后进行胸腹开窗分支血管腔内主动脉修复(FB-EVAR)。
我们回顾了2013年至2022年间连续接受FB-EVAR治疗的480例患者,这些患者使用了医生改良的腔内移植物(PMEG)或定制的支架型人工血管。从中,我们仅选择了接受开放或血管腔内弓修复及远端FB-EVAR治疗的动脉瘤累及升主动脉、主动脉弓和胸腹主动脉段(0-9区)的患者。定制装置在研究性器械豁免方案下使用。终点指标包括早期/院内死亡率、中期生存率、免于二次干预以及靶动脉稳定性。
共有22例患者,14例男性和8例女性,中位年龄为72±7岁。修复了13例夹层后和9例退行性主动脉瘤,平均最大直径为67±11mm。接受两阶段和三阶段修复策略的患者从初次主动脉手术到动脉瘤隔绝的时间分别为169天和270天。升主动脉和主动脉弓采用19例外科手术和3例血管腔内TAR手术进行治疗。3例(16%)外科弓手术在其他地方进行,围手术期细节不详。平均旁路、夹闭和循环阻断时间分别为295±57分钟、216±63分钟和46±11分钟。2例患者发生4例严重不良事件(MAE):两者均需要术后血液透析,1例术后发生心源性休克需要体外膜肺氧合,另1例需要清除急性慢性硬膜下血肿。胸腹主动脉瘤修复采用17例定制的腔内移植物和5例PMEG进行。无早期死亡。6例(27%)患者发生MAE。有4例(18%)脊髓损伤病例,其中3例(75%)在出院前症状完全缓解。平均随访30±17个月,期间有5例患者死亡,均与主动脉无关。8例患者需要≥1次二次干预,6条靶动脉显示不稳定(3例I型、1例IIIC型内漏;2例靶动脉狭窄)。Kaplan-Meier法估计的3年患者生存率、免于二次干预率和靶动脉稳定性分别为78±8%、56±11%和68±11%。
采用分期外科手术或血管腔内TAR及远端FB-EVAR进行全主动脉修复是安全有效的,发病率、中期生存率和靶动脉结局令人满意。临床影响本研究表明,通过全血管腔内或杂交方式修复整个主动脉是安全有效的,脊髓缺血发生率低。综合主动脉治疗团队中的心血管专科医生应确信,对于最复杂的退行性和夹层后胸腹主动脉瘤,分期修复可以安全地在患者中进行,其并发症情况与范围较小的修复相似。细致而精心的病例规划对于即刻和长期成功至关重要。